IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
Statement of transactions in own shares from November 06 to November 10, 2023 | BNP PARIBAS | |||||||||
Aggregated presentation by day and by market | ||||||||||
Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 266 | 110.07 | AQEU | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 710 | 110.64 | CEUX | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 213 | 111.09 | TQEX | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 2,630 | 110.49 | XPAR | ||||
* Two-digit rounding after the decimal | TOTAL | 3,819 | 110.52 |
Attachment
IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
- 14 November 2023 - 1 mins read
Statement of transactions in own shares from November 06 to November 10, 2023 | BNP PARIBAS | |||||||||
Aggregated presentation by day and by market | ||||||||||
Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 266 | 110.07 | AQEU | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 710 | 110.64 | CEUX | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 213 | 111.09 | TQEX | ||||
IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 2,630 | 110.49 | XPAR | ||||
* Two-digit rounding after the decimal | TOTAL | 3,819 | 110.52 |
Attachment
Related Press Releases
![TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
19 January 2024
7 mins read
TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA
![Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
13 November 2023
11 mins read
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
![IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
07 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
![Ipsen updates on QM-1114 regulatory process Ipsen updates on QM-1114 regulatory process](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
03 October 2023
5 mins read
Ipsen updates on QM-1114 regulatory process
![IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
26 September 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
![Ipsen nominates Pascal Touchon to its Board of Directors as new independent director Ipsen nominates Pascal Touchon to its Board of Directors as new independent director](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
04 September 2023
5 mins read
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
![Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
21 August 2023
15 mins read
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
![IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
18 July 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023
![Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
01 June 2023
2 mins read
Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023
![Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U. Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
26 May 2023
7 mins read